Orforglipron (Foundayo) Side Effects: ATTAIN-1 Trial Rates

The most common Foundayo (orforglipron) side effects are nausea, diarrhea, vomiting, constipation, and decreased appetite — all gastrointestinal, all dose-dependent, and most resolve within a few weeks of starting therapy or moving up a titration step^[1]. Foundayo carries the same boxed warning for medullary thyroid carcinoma as every other FDA-approved GLP-1 receptor agonist, and the same warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia in combination with insulin or sulfonylureas, allergic reactions, and pregnancy^[1]. This article walks through what the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report, how those rates compare to injectable Wegovy and Zepbound, and the practical questions patients keep searching for.

Most common side effects (ATTAIN-1 trial and FDA label)

Foundayo's approval was anchored on ATTAIN-1, a 72-week, randomized, double-blind, placebo-controlled phase 3 trial in adults with obesity or overweight without type 2 diabetes^[2]. The Eli Lilly approval press release for Foundayo identifies the most commonly reported adverse events in the ATTAIN program as the standard GLP-1 gastrointestinal cluster — nausea, constipation, diarrhea, vomiting, abdominal pain, indigestion, belching, and heartburn — plus headache, abdominal distension, fatigue, gas, and hair loss^[2].

The exact percentage point rates patients should consult are in Section 6 (Adverse Reactions) of the FDA Foundayo Prescribing Information^[1]. The qualitative pattern is identical to what semaglutide and tirzepatide produce in their respective trials: GI events are dose-dependent, peak in the days after a titration step, and taper as the body adapts. The FDA label is the source of truth — when in doubt, read Section 6 or ask your prescriber.

We are deliberately not inventing percentage figures the FDA Foundayo label has not yet itemized in publicly accessible copy. Once the full prescribing information is posted to DailyMed and the ATTAIN-1 manuscript is peer-reviewed, this article will be refreshed with the exact percentage point rates. The qualitative pattern — GI dominant, dose-dependent, adaptive over weeks — is consistent across every FDA-approved GLP-1 receptor agonist^[3][4].

GI side effects in detail

The four GI events that drive most Foundayo discontinuation in the early weeks are nausea, vomiting, diarrhea, and constipation. They share a mechanism: GLP-1 receptor activation slows gastric emptying, which is exactly the appetite suppression mechanism patients are paying for. The same slowed-emptying signal that makes you feel full after a few bites is what makes a too-large meal feel uncomfortable for hours afterward.

A common patient assumption is that an oral GLP-1 will be easier on the stomach than an injection. The trial data does not support that assumption. Foundayo is taken into the bloodstream and reaches the same GLP-1 receptors throughout the body — including the receptors on the GI tract — that injectable semaglutide and tirzepatide activate. The route of administration changes nothing about the downstream pharmacology^[2]. Foundayo's GI tolerability profile is broadly comparable to injectable semaglutide at comparable receptor activation, not better.

The single biggest tolerability lever is titration speed. The labeled Foundayo titration is six four-week steps from 0.8 mg up to the 17.2 mg maintenance dose^[1]. Patients who escalate too fast — chasing weight loss — typically pay for it with a week of GI symptoms after each step. Patients who stay on a step an extra cycle when they need to typically tolerate the eventual maintenance dose much better. See our Foundayo dosing guide for the full titration table.

Boxed warning: medullary thyroid carcinoma

Foundayo carries the same boxed warning as every other FDA-approved GLP-1 receptor agonist — Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Trulicity, Victoza, Rybelsus — for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC)^[1][3][4]. Foundayo is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)^[1].

The boxed warning is based on rodent data, not human data. In the original carcinogenicity studies submitted for liraglutide and subsequent GLP-1 agonists, rats and mice given long-term high-dose GLP-1 exposure developed thyroid C-cell tumors. The relevance of that signal to humans is uncertain — humans have far fewer C-cells than rodents and the receptor density and signaling differ — and large pharmacovigilance studies have not consistently replicated a thyroid cancer signal in humans on GLP-1 agonists. A 2023 nested case-control study in the French national health database (Bezin et al., Diabetes Care) reported an association between cumulative GLP-1 use and thyroid cancer that has been heavily debated for residual confounding^[5]. The current consensus is that the absolute risk in humans is very low if it exists at all, but the FDA has chosen to maintain the boxed warning across the class until cleaner long-term human data are available.

For our full review of the GLP-1 thyroid cancer evidence, including the Bezin paper, the Spanish cohort, and the more reassuring SELECT post-hoc data, see Does GLP-1 cause cancer? The MTC and thyroid evidence.

Less common but serious adverse events

The Foundayo FDA label includes the same Section 5 (Warnings and Precautions) safety topics as the rest of the GLP-1 class^[1]:

• Pancreatitis. Acute pancreatitis has been reported across the GLP-1 class in postmarketing surveillance. Foundayo should be discontinued if pancreatitis is suspected. Patients with a personal history of pancreatitis should discuss the risk-benefit with their prescriber^[1].
• Gallbladder disease (cholelithiasis, cholecystitis). GLP-1 agonists are associated with an increased rate of gallbladder events, particularly in the context of rapid weight loss^[3]. The Foundayo label warns for the same signal.
• Acute kidney injury. Severe GI side effects can cause dehydration, which in turn can cause acute kidney injury or worsen pre-existing chronic kidney disease. Patients should hydrate aggressively, especially during titration^[1].
• Hypoglycemia. Foundayo alone does not typically cause hypoglycemia in non-diabetic patients because GLP-1 only stimulates insulin in the presence of elevated glucose. Risk increases substantially when Foundayo is combined with insulin or a sulfonylurea^[1], which is why diabetic patients on those drugs need a dose reduction at the start of GLP-1 therapy.
• Hypersensitivity (allergic) reactions. Serious allergic reactions including anaphylaxis and angioedema have been reported across the GLP-1 class. Discontinue and seek emergency care for any signs of a severe allergic reaction^[1].
• Suicidal thoughts and behavior monitoring. The FDA reviewed the GLP-1 class for a suicidal ideation signal in 2024 and did not find a causal relationship, but the labels still recommend monitoring for new or worsening depression, suicidal thoughts, or behavior changes, particularly in patients with a history of mood disorders.
• Pulmonary aspiration during anesthesia. Because GLP-1 agonists slow gastric emptying, patients on Foundayo undergoing elective surgery or any procedure requiring sedation should follow the American Society of Anesthesiologists guidance, which currently recommends considering withholding the drug or extending fasting on procedure day to reduce aspiration risk^[6].

Pregnancy and fertility

Foundayo is contraindicated in pregnancy. The FDA recommends discontinuing GLP-1 receptor agonists at least two months before a planned pregnancy because the drug crosses the placenta and animal reproductive studies show fetal harm at therapeutic exposures^[7]. The two-month washout reflects orforglipron's elimination half-life and the goal of clearing the drug before organogenesis.

A separate consideration for women of reproductive age: Foundayo's prescribing information includes a specific oral contraceptive interaction. Per Section 7.1 of the Foundayo PI, women on oral contraceptives should add a barrier method (or switch to a non-oral hormonal method, an IUD, or an implant) for 30 days after starting Foundayo and 30 days after each dose increase^[1]. For the broader fertility and pregnancy picture across the GLP-1 class, see GLP-1s, pregnancy, PCOS, and women's reproductive health.

How Foundayo side effects compare to injectable GLP-1s

The honest answer: rates look broadly similar across the class. Wegovy (semaglutide) reported nausea in roughly 30-44% of patients in STEP-1^[3], vomiting in 18-24%, diarrhea in 23-30%, and constipation in 17-24%. Zepbound (tirzepatide) reported similar rates in SURMOUNT-1^[4]. Foundayo's ATTAIN program identifies the same GI cluster as the most common adverse events^[2], and the FDA Foundayo label includes the same warnings as Wegovy and Zepbound^[1].

The fair statement is that oral delivery does not meaningfully change the GI tolerability profile of a GLP-1 agonist. The differences between Foundayo and the injectables are:

• Daily vs weekly dosing. Foundayo is a once-daily pill; Wegovy, Ozempic, Zepbound, and Mounjaro are once-weekly injections. A daily oral dose creates a smoother concentration curve with less peak-to-trough swing, which some patients tolerate better.
• No injection site reactions. Foundayo eliminates the redness, itching, and lump at the injection site that some injectable patients experience.
• Effect size. Foundayo's 17.2 mg labeled-dose efficacy (~11.1% mean weight loss in non-diabetic adults) sits below injectable semaglutide (~14.9% in STEP-1) and well below tirzepatide (~20.9% in SURMOUNT-1). The trade-off is convenience vs maximum weight loss.

For the side-by-side trial-arm comparison and price breakdown, see our Foundayo vs Wegovy vs Zepbound comparison and the broader GLP-1 side effects investigation.

Managing side effects

Most Foundayo GI side effects are manageable with simple practical changes, especially during the first weeks on a new dose. The four highest-leverage interventions:

1. Slow titration. The single biggest lever. If a step makes you feel terrible for more than a few days, ask your prescriber whether you can stay on the previous dose for an extra 4 weeks before trying again. The labeled schedule is a maximum, not a minimum.
2. Smaller, more frequent meals. Slowed gastric emptying makes large meals feel uncomfortable for hours. Stop eating at the first sign of fullness. Most patients find that 4-5 small meals per day are tolerated far better than 2-3 normal-sized ones.
3. Hydration. Aim for at least 64 oz of non-caloric fluid daily, more if you have any vomiting or diarrhea. Dehydration is the mechanism behind the kidney injury warning on the Foundayo label^[1].
4. Antiemetics for severe nausea. Prescribers can prescribe ondansetron (Zofran) or prochlorperazine for short courses if titration adjustment is not enough. Do not self-medicate without checking with your prescriber.

For a full practical playbook on GLP-1 nausea management across the class, see GLP-1 nausea management practical guide.

When to call your doctor

Frequently asked questions

Are orforglipron side effects worse than Ozempic side effects?

No. The FDA Foundayo label and the ATTAIN-1 trial show the same GI side effect profile as injectable semaglutide — nausea, diarrhea, vomiting, constipation, and decreased appetite. Rates are broadly similar across the GLP-1 class because the mechanism is the same. Oral delivery does not make the GI effects worse^[1][3].

How long do orforglipron side effects last?

Most GI side effects appear in the first days after starting Foundayo or after a dose increase, then taper over 2 to 4 weeks as the body adapts. Persistent symptoms beyond a month, or severe symptoms at any point, should be reviewed with the prescribing clinician — sometimes the answer is to slow titration or stay an extra cycle on the current dose.

Can orforglipron cause weight regain when you stop?

Stopping any GLP-1 typically causes some weight regain because the appetite signal returns. Long-term post-discontinuation data on orforglipron specifically has not been published yet, but the pattern documented for injectable semaglutide is that most patients regain a substantial fraction of lost weight within a year after stopping. Plan the off-ramp with a clinician.

Does taking orforglipron with food help with nausea?

Foundayo is specifically labeled to be taken on an empty stomach with plain water^[1], so you cannot take it with food. To reduce nausea, focus on the rest of the day: eat smaller meals, avoid greasy or very rich foods, stay hydrated, and stop eating at the first sign of fullness. Your prescriber can also slow the titration schedule.

Is orforglipron safer than injectable GLP-1s?

The Foundayo FDA label carries the same boxed warning for medullary thyroid carcinoma and the same warnings for pancreatitis, gallbladder disease, kidney injury, hypoglycemia in combination with insulin or sulfonylureas, allergic reactions, and pregnancy contraindication as Wegovy, Ozempic, and Zepbound^[1][3][4]. The safety profile is broadly the same across the class.

Should I stop orforglipron if I get side effects?

Mild to moderate GI side effects in the first weeks are expected and usually do not require stopping — they typically resolve as the body adapts. Stop and call the prescriber for severe persistent vomiting, severe abdominal pain (possible pancreatitis), neck swelling or trouble swallowing (possible thyroid issue), signs of an allergic reaction, or signs of dehydration.

Bottom line

• The most common Foundayo (orforglipron) side effects are GI: nausea, diarrhea, vomiting, constipation, and decreased appetite. All dose-dependent, most resolve within weeks^[1][2].
• Foundayo carries the same boxed warning for medullary thyroid carcinoma as the rest of the GLP-1 class, based on rodent data. Contraindicated with personal or family history of MTC or MEN 2^[1].
• The same Section 5 warnings as Wegovy and Zepbound: pancreatitis, gallbladder disease, kidney injury, hypoglycemia (in combination with insulin or sulfonylureas), allergic reactions, anesthesia aspiration risk, and pregnancy contraindication^[1][6][7].
• Oral delivery does not meaningfully change GI tolerability versus injectable GLP-1s. The differences are dosing frequency, no injection site reactions, and a somewhat smaller effect size at the labeled maintenance dose.
• The biggest tolerability lever is titration speed. Stay on a step longer if you need to.

Related research

• Foundayo (orforglipron) FDA approval deep-dive — the full ATTAIN-1 trial data and the approval narrative
• How to take Foundayo — daily protocol, titration schedule, missed-dose rules
• Foundayo vs Wegovy vs Zepbound comparison — head-to-head efficacy, safety, and pricing
• Does GLP-1 cause cancer? MTC and thyroid evidence — the boxed warning and what the human data actually show
• GLP-1 nausea management practical guide — the full playbook for GI side effects across the class
• GLP-1s, pregnancy, PCOS, and women's health — the two-month washout rule and the contraceptive overlap
• GLP-1 side effects: what the trials actually showed — class-wide trial-rate comparison

Important disclaimer. This article is educational and does not constitute medical advice. Adverse event language is sourced from the FDA Foundayo (orforglipron) Prescribing Information and the ATTAIN-1 phase 3 readout summarized in Eli Lilly's approval press release. Where the exact percentage point rates were not yet itemized in publicly accessible label copy at the time of writing, we described the event qualitatively and cited the FDA label rather than inventing a number. Always verify with your prescribing clinician and consult the most current FDA prescribing information before making any decisions about a prescription medication.